2 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
Follow ECOG Performance Status Score of 0 or 1: new trials by email Literature Review of ECOG Performance Status Score of 0 or 1 trials Research Report on ECOG Performance Status Score of 0 or 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer Serplulimab，Platinum-based Chemotherapy，Aspirin - Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 43 | 2024-10-01 | 2024-08-15 |
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · folfirinox (1)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
France (1)